HOME >> BIOLOGY >> NEWS
Immune system's distress signal tells bacteria when to strike back

The human opportunistic pathogen, Pseudomonas aeruginosa, has broken the immune system's code, report researchers from the University of Chicago, enabling the bacteria to recognize when its host is most vulnerable and to launch an attack before the weakened host can muster its defenses.

In the 29 July 2005 issue of Science, the researchers show how this lethal organism detects interferon-gamma, a chemical messenger the immune system uses to coordinate its efforts to get rid of bacteria. When these bacteria intercept this message, they recognize it as a threat, assess their own numbers and, if they have sufficient strength, activate genes that quickly transform them from benign passengers in the bowel into deadly blood-stream invaders.

"Most of the time these microbes are content to live and grow in our intestines," said John Alverdy, M.D., professor of surgery at the University of Chicago and director of the study. "They don't feel the need or even look for the opportunity to attack. But when they detect a threat, they have a remarkably sophisticated defense plan, based, unfortunately, on the notion that the best defense is an overwhelming offense."

Pseudomonas aeruginosa is ubiquitous. It lives in all sorts of moist places, including damp soil and on the surface of vegetables, as well as in streams, faucets and drinking fountains. It is often a long-term bowel tenant, colonizing the intestines of about three percent of healthy people.

In the bowel this germ is usually harmless, but it can turn deadly, causing gut-derived sepsis. It is also a frequent cause of infections after major surgery.

Physicians have theorized, said Alverdy, that germs such as Pseudomonas are always "probing for a weakness in the host and are ready and willing to strike whenever they find one." He and his colleagues, however, are testing an alternative theory: that "bacteria are perfectly content in their niche until signals from the
'"/>

Contact: John Easton
John.Easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
28-Jul-2005


Page: 1 2 3

Related biology news :

1. Immune system escape hatch gives cancer cells traction
2. Immune antibodies penetrate neurons to clear Alzheimers-linked amyloid
3. Immune response to cancer stem cells may dictate cancers course
4. Immune systems in breast cancer survivors who suffer from fatigue fail to shut off after therapy
5. Immune response to HIV in the brain
6. Immune substances may help antibody-based drugs fight cancer
7. Immune cell receptors act in combination to regulate attack
8. Immune system has evolved to prevent autoimmune disease
9. Immune cells known as macrophages linked to growth of lymph vessels in eyes, scientists discover
10. Immune cells genetic jam session is controlled by cell division machinery
11. Immune systems initial response to cancer under study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Immune system distress signal tells bacteria when strike back

(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: